Navigation Links
Pevion's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
Date:10/11/2011

BERN, Switzerland, October 11, 2011 /PRNewswire/ --

Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate. The announcement further included the results of the largest, international representative epidemiological survey to date on recurrent vulvovaginal candidiasis (RVVC), confirming that 7% of adult women suffer from the disease.

The newly announced data come from the group of volunteers vaccinated with the intramuscular high dose of PEV7 and showed significantly increased immunogenicity over the previously vaccinated low-dose group, while confirming the excellent safety profile customary for virosome-delivered vaccines. Particularly relevant for the postulated mode-of-action of PEV7 was the strong immune response detected in vaginal and cervical samples. All volunteers showed a mucosal immune response with consistently high titers across the group.

"An immune response of this magnitude in the cervicovaginal compartment is very encouraging with regards to the therapeutic potential of the vaccine," stated Jean-Paul Prieels, former Head of Vaccine R&D at GlaxoSmithKline and recently elected  Board Member at Pevion. "After seeing the first positive immunogenicity data from the low dose group, we defined criteria on what immunogenicity outcome we would regard as best case for the high dose. We are delighted that these criteria have been met in full. We are now following the level of immune response over time and see first promising signs in terms of mucosal antibody persistence."

In order to further validate the disease burden and the commercial potential of PEV7, Pevion mandated the largest, international representative epidemiological survey on RVVC among 6'000 women, generating robust data on prevalence, incidence and the age structure of the RVVC patient population. The study
'/>"/>

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
2. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
3. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
4. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
5. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
6. ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
7. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
8. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
9. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
10. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
11. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 2014 The report provides qualitative insights ... important sub-segments of the market, in order to provide ... growth rates and market sizes for each sub-segment of ... rapid growth. It also includes analysis of the company ... include the financial performances, product portfolios, and developments of ...
(Date:11/27/2014)... The Europe Thermal Protective Clothing market report defines ... forecasts. It estimates the market to reach $577.9 ... 7.5%, from 2013 to 2018. , Browse through ... market report for a glimpse of the market ... and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html , Protective ...
(Date:11/27/2014)... , Nov. 27, 2014 Research ... "Global Palmitic Acid Industry Report 2014" report ... The Global Palmitic Acid Industry Report ... current state of the global palmitic acid industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:11/27/2014)... 2014 Spartan Bioscience today announced that ... Drug Safety (MFDS) regulatory approval for its Spartan ... in less than 60 minutes from a non-invasive cheek ... aid for doctors to determine therapeutic strategies for drugs ... some of the world’s most commonly prescribed drugs such ...
Breaking Biology Technology:Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3
... SoluLinK, Inc., a leader in,next-generation conjugation products ... of a new product, NanoLink(TM) Streptavidin Magnetic,Microspheres. ... of any commercially available polymer-encapsulated streptavidin,magnetic microsphere. ... throughput robotic applications where high biotin loads,must ...
... The automation of,transaction-based processing is finding new ... States. Foresight Corporation of Dublin, Ohio reports,growth ... installations of Transaction,Insight(R) - the leading platform ... techniques enable healthcare organizations to,cut operational costs ...
... May 28 NanoLogix, Inc. (Pink,Sheets: NNLX) a ... NanoLogix personnel will showcase company technology at ... in Boston, June 1-5 2008. The ASM,meeting is ... will be Dr. Sergey Gazenko and CEO Bret ...
Cached Biology Technology:SoluLinK Introduces NanoLink(TM) Streptavidin Magnetic Microspheres 2New Trend Sweeping Nation's Health Plans: Transaction Automation 2NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update 2
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... respiratory syndrome (SARS) epidemic in China has lessons to ... other respiratory diseases, according to new research appearing in ... available online. , Hospitals were epicenters of SARS transmission ... hospitals with especially severe outbreaks, the researchers looked at ...
... is the ultimate enzyme responsible for all aerobic life ... a crucial component of the cellular machinery that generates ... might expect that scientists would have a clear understanding ... James P. Collman, professor emeritus of chemistry at Stanford ...
... epigenetic variations ensure that no two people are exactly ... cancers. Now, researchers have the tools and the ... cancer therapies, enabling them to create more effective therapies ... Meeting of the American Association for Cancer Research, researchers ...
Cached Biology News:Study identifies risk factors for spread of respiratory infections in hospitals 2Researchers create artificial enzyme that mimics the body's internal engine 2Researchers create artificial enzyme that mimics the body's internal engine 3Genes and biomarkers that allow doctors to choose the right therapy for the right patient 2Genes and biomarkers that allow doctors to choose the right therapy for the right patient 3Genes and biomarkers that allow doctors to choose the right therapy for the right patient 4Genes and biomarkers that allow doctors to choose the right therapy for the right patient 5Genes and biomarkers that allow doctors to choose the right therapy for the right patient 6
... reagents and supplies, for 10 chips, ... to perform protein analysis with 10 ... system. Supplied are 3 x 520 ... stain, 60 microliters Pro260 ladder (10-260 ...
...
... Fermentation System to achieve high experimental ... maximum information output 4 up ... with small-scale requirements provides users with ... E.coli, Pichia pastoris, yeast, fungi or ...
... preactivated with carbonyl diimidazole chemistry that covalently ... PS10 array contains the same binding chemistry ... an updated hydrophobic barrier coating. These arrays ... diameter spots spatially compatible with one column ...
Biology Products: